Skip to main content

Glucotrack, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

GCTK$1.39-32.2%Stored close · as of Oct 29, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statement of Changes in Stockholders’ Equity

(in thousands of US Dollars except share data) (unaudited)

In thousands of US Dollars (except share data)
Common Stock
Numbers of Shares · Amount · Additional Paid-in Capital · Receipts on account of shares · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity
Balance as of December 31, 2024 (Audited)13,409$-(*)$119,230$228$(8)$(132,450)$(13,000)
Loss for the period-----(15,760)(15,760)
Other comprehensive income----50-50
Stock-based compensation--121---121
Issuance of Common Stock upon the completion of public offerings, net of offering expenses of $539665,052110,714---10,715
Stock split adjustment58,886-(*)-----
Cashless exchange of warrants into Common Stock162,063-(*)20,625---20,625
Balance as of September 30, 2025 (Unaudited)899,410$1$150,690$228$42$(148,210)$2,751
Balance as of December 31, 2023 (Audited)3,482$-(*)$112,986$48$16$(109,853)$3,197
Loss for the period-----(12,503)(12,503)
Other comprehensive income----(11)-(11)
Stock-based compensation--239---239
Issuance of restricted shares as compensation towards directors73-(*)126(48)--78
Restricted shares to be issued as compensation towards directors---100--100
Issuance of Common Stock upon private placement transaction67-(*)500-500
Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement17-(*)-----
Exercise of prefunded warrants into shares330-(*)-----
Exchange of warrants into shares599-(*)-----
Issuance of detachable warrants through private placements transactions2,6352,635
Issuance of shares and warrants as settlement of financial liabilities243-(*)1,743---1,743
Balance as of September 30, 2024 (Unaudited)4,811$-$118,229$100$5$(122,356)$(4,022)
Balance as of June 30, 2025 (Unaudited)899,410$-(*)$150,649$228$41$(144,039)$6,880
Loss for the period-----(4,171)(4,171)
Other comprehensive income----1-1
Stock-based compensation--41---41
Balance as of September 30, 2025 (Unaudited)899,410$1$150,690$228$42$(148,210)$2,751
Balance as of June 30, 2024 (Unaudited)4,568$-(*)$113,908$50$22$(117,269)$(3,289)
Loss for the period-----(5,087)(5,087)
Other comprehensive income-(17)-(17)
Stock-based compensation--11---11
Issuance of detachable warrants through private placements transactions-(*)2,567--2,567
Restricted shares to be issued as compensation towards directors-50--50
Issuance of shares and warrants as settlement of financial liabilities243-(*)1,743---1,743
Balance as of September 30, 2024 (Unaudited)4,811$-$118,229$100$5$(122,356)$(4,022)
(*)Represents amount lower than $1.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.